Patents Assigned to X4 Pharmaceuticals (Austria) GmbH
  • ANTIBODIES TARGETING A GALACTAN-BASED O-ANTIGEN OF K. PNEUMONIAE
    Publication number: 20230220055
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Application
    Filed: August 16, 2022
    Publication date: July 13, 2023
    Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria SZIJARTO, Gábor NAGY, Luis GUACHALLA, Zehra VISRAM, Eszter NAGY, Jolanta Katarzyna LUKASIEWICZ
  • Antibodies targeting a galactan-based O-antigen of K. pneumoniae
    Patent number: 11466074
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 11, 2022
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria Szijarto, Gábor Nagy, Luis Guachalla, Zehra Visram, Eszter Nagy, Jolanta Katarzyna Lukasiewicz
  • MDR E. COLI SPECIFIC ANTIBODY
    Publication number: 20210162034
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 3, 2021
    Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • MDR specific antibody
    Patent number: 10940191
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 9, 2021
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • KLEBSIELLA PNEUMONIAE O3 SPECIFIC ANTIBODIES
    Publication number: 20200339668
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 29, 2020
    Applicants: X4 Pharmaceuticals (Austria) GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA